, , 2017.
, PCNA Guideline for the Prevention, p.349
, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A 350 Report of the American College of Cardiology, American Heart Association Task Force on Clinical, p.351
, Practice Guidelines. Circulation, vol.138, issue.17, pp.426-483, 2018.
Incidence and prognosis of resistant hypertension in 354 hypertensive patients, Circulation, vol.353, issue.13, pp.1635-1677 ,
, , p.356
Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for 357 Geographic and Racial Differences in Stroke (REGARDS), Am Heart J, vol.181, pp.43-51, 2016. ,
Resistant hypertension: what the 359 cardiologist needs to know, Eur Heart J, vol.36, issue.40, 2015. ,
Empagliflozin, Cardiovascular 362 Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine, vol.363, p.11, 2015. ,
Emerging Drug Classes and Their Potential Use in,
URL : https://hal.archives-ouvertes.fr/hal-02512565
, Hypertension. Hypertension, p.366, 2019.
, Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes 367 Care, vol.38, pp.420-428, 2015.
, , p.369
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus 370 and Hypertension by Background Antihypertensive Medication, Hypertension, issue.6, pp.1355-1364, 1979. ,
, , p.373
The effect of empagliflozin on arterial stiffness and heart rate 374 variability in subjects with uncomplicated type 1 diabetes mellitus, Cardiovasc Diabetol, vol.13, p.15, 2014. ,
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular 377 resistance in patients with type 2 diabetes, Diabetes Obes Metab, vol.17, issue.12, pp.1180-93, 2015. ,
, , p.380
, How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the
, Diabetes Care, vol.41, issue.2, pp.356-363, 2018.
Resistant hypertension in diabetes mellitus, Curr, vol.383 ,
, , vol.14, pp.516-384, 2014.
, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 387 Pressure: the JNC 7 report, vol.289, pp.2560-72, 2003.
, , p.389
, , p.390
Effects of intensive 391 blood-pressure control in type 2 diabetes mellitus. The New England journal of medicine, vol.362, pp.1575-85, 2010. ,
395 Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated 396 systematic review and meta-analysis, Lancet, vol.387, p.21, 2016. ,
Intensive Blood Pressure 398 Targets for Diabetic and Other High-Risk Populations: A Pooled Individual Patient Data Analysis ,
, Hypertension, vol.71, issue.5, pp.833-839, 1979.
, , vol.401
, , vol.402
A Randomized Trial of 403 Intensive versus Standard Blood-Pressure Control, The New England journal of medicine, vol.373, issue.22, pp.2103-2119, 2015. ,
, Resistant hypertension" was a post-hoc presumptive diagnosis. ACE indicates angiotensin-converting enzyme
, BMI (category), eGFR (category), treatment, rHT, and treatment by resistant hypertension interaction, *HR by multivariable Cox regression with the following variables: age, sex, region, HbA1c (category)
, way interactions as fixed effects (for details on other fixed effects and linear covariates, see "statistical analysis" section)